Innate Pharma S.A.
IPH.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €117,586 | €159,625 | €200,445 | €270,997 |
| - Cash | €66,396 | €70,605 | €84,225 | €103,756 |
| + Debt | €30,995 | €39,893 | €42,251 | €44,251 |
| Enterprise Value | €82,185 | €128,913 | €158,471 | €211,492 |
| Revenue | €12,622 | €51,901 | €49,639 | €12,112 |
| % Growth | -75.7% | 4.6% | 309.8% | – |
| Gross Profit | -€31,859 | €5,619 | €6,011 | -€34,892 |
| % Margin | -252.4% | 10.8% | 12.1% | -288.1% |
| EBITDA | -€50,990 | -€1,839 | -€61,295 | -€43,229 |
| % Margin | -404% | -3.5% | -123.5% | -356.9% |
| Net Income | -€49,471 | -€7,570 | -€58,103 | -€52,809 |
| % Margin | -391.9% | -14.6% | -117.1% | -436% |
| EPS Diluted | -0.61 | -0.094 | -0.73 | -0.66 |
| % Growth | -548.2% | 87.1% | -10.6% | – |
| Operating Cash Flow | -€6,896 | -€32,558 | -€19,154 | -€58,457 |
| Capital Expenditures | -€391 | -€2,351 | -€1,122 | -€1,330 |
| Free Cash Flow | -€7,287 | -€34,909 | -€20,276 | -€59,787 |